Early Detection of Complications During Immunotherapy for Haematological Malignancy

Summary

Aims * To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications * Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years
* Patients diagnosed with haematologic malignant disease (e.g. malignant lymphoma)
* Patients scheduled for treatment with CART or BsAbs

Exclusion Criteria:

* Patient is pregnant
* Patient has a pacemaker
* Patient is allergic to one or more of the materials that the equipment consists of
* Investigator deems patient not able to comply with participation in the study

Conditions3

Browse More Trials